Absstract of: WO2023088265A1

A blood sugar level obtaining apparatus, a blood sugar level measurement apparatus, and a method. The blood sugar level obtaining apparatus comprises a pressure obtaining module (110), a spectral intensity obtaining module (120), and a result obtaining module (130); the pressure obtaining module (110) is used for obtaining pressure data of a part under test of a user acting on a measurement board in a measurement apparatus; the spectral intensity obtaining module (120) is used for obtaining spectral signal intensity acquired when a spectrometer irradiates the measurement board, wherein the spectral signal intensity and the pressure data are obtained in a same time period; the result obtaining module (130) is used for obtaining a blood sugar level measurement result on the basis of the pressure data and the spectral signal intensity.

Absstract of: WO2022013140A1

A continuous glucose monitoring (CGM) system is configured to detect a reinserted CGM sensor. The system reads a CGM sensor identifier stored in a CGM sensor unit memory in response to insertion of a CGM sensor into the skin of user. The system compares the identifier to any previously-stored identifiers of previously-inserted CGM sensors. If the identifier does not match a previously-stored identifier, indicating a newly-inserted sensor, the identifier is stored and CGM may begin. If the identifier matches a previously- stored identifier, indicating a reinserted sensor, a usage limit corresponding to the stored identifier of the reinserted sensor is then checked to determine whether it has been met. If it has, CGM is halted. If it has not, CGM may continue with the reinserted CGM sensor. Methods of detecting reinsertion and usage limits of a CGM sensor are also provided, as are other aspects.

Absstract of: EP4183326A1

Method and System for providing a signal from an insulin pump, artificial pancreas, or another insulin delivery device as a source of information for improving the accuracy of a continuous glucose sensor (CGS). The effect of using insulin information to enhance sensor accuracy is most prominent at low blood glucose levels, i.e. in the hypoglycemic range, which is critical for any treatment. A system for providing a filtering/state estimation methodology that may be used to determine a glucose state estimate at time t-τ. The estimation may be extrapolated to some future time t and then the extrapolated value is used to extract the blood glucose component. The blood glucose component of the extrapolation and the output of the CGS are weighted and used to estimate the blood glucose level of a subject.

Absstract of: GB2613032A

A system and method of calibrating a model used in a device for non-invasive in vivo measurement of an analyte concentration using Raman spectroscopy. The device comprises an optical source for providing an optical signal and an optical detector to receive a Raman scattered optical output. The method (Fig.2) comprises, in response to the laser source being directed to a user’s skin 213, gathering Raman scattered radiation from the user’s skin and based on that, calibrating the model based on reference data and the received Raman spectra over an extended period of days. Once the model is calibrated, storing the model for use. The calibration period can be 14 days or 20 days or between 20 and 28 days. The method may comprise receiving reference data from an invasive blood glucose monitoring device.

Absstract of: EP4183331A1

A method includes monitoring, via a device including an electrochemical cell, an electrical current that is proportional to an impedance of the electrochemical cell, and responsive to determining that the electrical current satisfies a threshold, measuring, via the device, a plurality of impedances of the electrochemical cell corresponding to a plurality of frequencies. The method further includes determining a charge transfer conductance and a solution resistance based on the plurality of impedances at fewer than four of the corresponding plurality of frequencies and determining the presence of electrochemical interference based on the solution resistance and the charge transfer conductance. The method further includes outputting an alert based on the determination of the presence of electrochemical interference.

Absstract of: WO2016161254A1

Methods and systems are disclosed analyzing a glucose level of a person having diabetes. The method, in at least one example, comprises receiving into a computing device a plurality of measured glucose values from a continuous glucose monitoring system coupled to a person having diabetes, analyzing the plurality of measured glucose values with a probability analysis tool on the computing device to determine a glucose threshold (g lc ), and a boundary (g ρ ) glucose value at a probability threshold where the person having diabetes requires at least a predetermined insulin dose, and comparing, with the computing device, the boundary glucose value (g ρ ) to the glucose threshold (g lc ), wherein if the boundary glucose value (g ρ ) is greater than the glucose threshold (g lc ) then the computing device performs an alert on a user interface.

Absstract of: WO2023086632A1

A glucose monitoring system comprising a sensor control device comprising an analyte sensor coupled with sensor electronics, the sensor control device configured to transmit data indicative of an analyte level of a subject, and a reader device. The reader device comprises a wireless communication circuitry configured to receive the data indicative of the analyte level and a glycated hemoglobin level for the subject, a non- transitory memory, and at least one processor communicatively coupled to the non- transitory memory and the analyte sensor and configured: calculate a plurality of personalized glucose metrics for the subject using at least one physiological parameter and at least one of the received data indicative of the analyte level or the received glycated hemoglobin level, and a display, on a display of the reader device, a report comprising a plurality of interfaces including at least two or more of the received data indicative of the analyte level, the received glycated hemoglobin level, or the calculated plurality of personalized glucose metrics, wherein the plurality of interfaces comprising the report are based on a user type.

Absstract of: WO2023084453A1

The present invention relates to a method and system for determining risk data (1) concerning injury in a user's foot, for designing and developing customised insoles for the early management of biomechanical alterations in diabetic patients, supported by a telemedicine platform and 15 embedded digital modules with protocols and software applications, for acquiring and integrating patient information by means of commercial specialised electronic devices integrated into the platform and which provided step-by-step assistance to an expert (8) for the smart automated design and remote production of customised therapeutic insoles adapted to the size and morphology of each user with diabetic foot syndrome.

Absstract of: WO2023086482A1

A device for delivering medicament to a user is disclosed. The device comprises a reservoir for storing medicament; an infusion catheter fluidly communicating with the reservoir to deliver the medicament into a subcutaneous layer of the user; a pump fluidly communicating with the reservoir and infusion catheter for pumping the medicament from the reservoir though the infusion catheter; an introducer needle movable within the infusion catheter, the introducer needle configured to facilitate (a) insertion of the infusion catheter into a subcutaneous layer of the user and (b) retraction of the introducer needle after insertion of the infusion catheter to enable delivery of medicament through the infusion catheter; and a sensor for continuously monitoring glucose level in the user, wherein the sensor is configured to (a) engage the introducer needle and/or the infusion catheter and (b) simultaneously advance along with the infusion catheter during the insertion into the subcutaneous layer of the user by the introducer needle.

Absstract of: WO2023086980A1

Described herein are preserved formulations of insulin-Fc fusions. The formulations include insulin-Fc fusions having prolonged pharmacokinetic and pharmacodynamic profiles sufficient for once weekly administration in the treatment of diabetes and are sufficiently stable to allow for storage and use without unacceptable loss of chemical or physical stability.

Absstract of: WO2023086232A1

In some examples, a system for monitoring glucose includes processing circuitry and a glucose monitor comprising one or more monitor electrodes and one or more working electrodes, wherein a first chemistry stack is disposed on at least one of the monitor electrode(s) and a second chemistry stack is disposed on at least one of the working electrode(s). The processing circuitry may be configured to measure one or more calibration values of an operating parameter of the monitor electrode(s), retrieve one or more pre-calibration values of the operating parameter of the monitor electrode(s), wherein the pre-calibration value(s) were measured before the calibration value, determine one or more delta values using the calibration value(s) and the pre-calibration value(s), and calibrate glucose values sensed by the working electrode(s) using the delta value(s).

Absstract of: US2023149639A1

A syringe, having a front portion carrying a hollow, axially extending needle, a container, running from said front portion and forming a container rear end portion, a plunger, extending and being movable axially in the container, the needle rear end being in fluid connection with the container and the plunger being arranged to suck liquid, e.g. a liquid comprising insulin, through the needle when drawn away from the needle and to discharge liquid through the needle when pushed towards the needle, the plunger having a piston portion, turned to the needle rear end, and a coupling portion arranged to co-act with the piston portion for moving the piston portion in the container.

Absstract of: US2023148917A1

The present invention relates generally to systems and methods for measuring an analyte in a host. More particularly, the present invention relates to systems and methods for transcutaneous measurement of glucose in a host.

Absstract of: US2023148916A1

In some examples, a system for monitoring glucose includes processing circuitry and a glucose monitor comprising one or more monitor electrodes and one or more working electrodes, wherein a first chemistry stack is disposed on at least one of the monitor electrode(s) and a second chemistry stack is disposed on at least one of the working electrode(s). The processing circuitry may be configured to measure one or more calibration values of an operating parameter of the monitor electrode(s), retrieve one or more pre-calibration values of the operating parameter of the monitor electrode(s), wherein the pre-calibration value(s) were measured before the calibration value, determine one or more delta values using the calibration value(s) and the pre-calibration value(s), and calibrate glucose values sensed by the working electrode(s) using the delta value(s).

Absstract of: US2023148910A1

A lifestyle coaching system for lifestyle intervention in disease management is provided. The lifestyle coaching system detects a patient performing various lifestyle activities, such as a workout or stress-inducing activity, as part of determining and optimizing real time or near-real time coaching output that is displayed to a patient via a user device. The provided lifestyle coaching system is able to detect a start and end time of each of the patient's workouts despite receiving the patient's heart rate data at a low sampling rate from a fitness tracking device by combining the low sample rate heart rate data with secondary factors indicative of patient working out. The provided lifestyle coaching system is also able to detect when an elevated heart rate of a patient is due to stress rather than exercise.

Absstract of: US2023154625A1

Method and system including displaying a first representation of a medication treatment parameter profile, displaying a first representation of a physiological profile associated with the medication treatment parameter profile, detecting a modification to a segment of the medication treatment parameter profile, displaying a modified representation of the medication treatment parameter profile and the physiological profile based on the detected modification to the segment of the medication treatment parameter profile, modifying an attribute of the first representation of the medication treatment parameter profile, and modifying an attribute of the first representation of the physiological profile are provided.

Absstract of: AU2023202712A1

An encapsulation device system for therapeutic applications such as but not limited to regulating blood glucose. The system may comprise an encapsulation device with a first oxygen sensor integrated inside the device and a second oxygen sensor disposed on an outer surface of the device, wherein the sensors allow for real-time measurements (such as oxygen levels) related to cells (e.g., islet cells, stem cell derived beta cells, etc.) housed in the encapsulation device. The system may also feature an exogenous oxygen delivery system operatively connected to the encapsulation device via a channel, wherein the exogenous oxygen delivery system is adapted to deliver oxygen to the encapsulation device.

Absstract of: AU2023202651A1

The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and/or encrypting data.

Absstract of: AU2023202630A1

Systems, methods, and devices provide alarms and alerts in an on-body networked diabetes management system. Methods may include receiving glucose sensor data from a continuous glucose monitor and determining a dosage of insulin delivery based at least in part on the glucose sensor data. The method may include detecting an alarm or alert condition, and sending a wireless communication regarding the alarm or alert condition to a remote user-interface device. The method may include triggering an audible, visual, or haptic alarm or alert on the insulin delivery device unless an acknowledgement of the alarm or alert condition is received within a predetermined period of time.

Absstract of: AU2021358022A1

A delivery device for delivering medicament, such as insulin, to a patient includes a housing and a base enclosing an inner cavity. Enclosed within the housing is a reservoir for containing a medicament, a delivery mechanism for delivering the medicament to the patient, and a pump in fluid communication with the reservoir and delivery mechanism. The base has an integrally formed fluid channel covered by a flexible membrane in fluid communication with the reservoir and the delivery mechanism. A peristaltic pump mechanism includes a cam assembly having a plurality of cams and cam follower assembly with a plurality of protrusions to sequentially engaging the flexible membrane to advance the fluid through fluid channel.

Absstract of: WO2022011345A1

This invention is directed to towards methods of identifying a subject with insulin resistance. For example, this invention is drawn to adjusting C-peptide urinary excretion rate for average glucose concentration to identify a subject with insulin resistance.

Absstract of: WO2022010698A1

A therapeutic hybrid microneedle patch mimics the inherent counter-regulatory effects of β-cells and α-cells for blood glucose management by dynamically releasing insulin or glucagon contained within the microneedles of the therapeutic hybrid microneedle patch. The two types of microneedles in the therapeutic hybrid microneedle patch share a co-polymerized matrix but comprise different ratios of the key monomers to be 'dually-responsive' to both hyper- and hypoglycemic glucose conditions. In a type 1 diabetic mouse model, the therapeutic hybrid microneedle patch effectively controls hyperglycemia while minimizing the occurrence of hypoglycemia in the setting of insulin therapy and simulated delayed meal or insulin overdose. In other embodiments, multiple patches are applied to achieve similar results.

Absstract of: US2023141293A1

An insulin pump bolus infusion control method. A control module of a pump body controls the pump body to start a bolus infusion control mode after receiving a function starting signal; in the bolus infusion control mode, a bolus key of a control terminal or a bolus key of an insulin pump body sends an infusion dosage signal to the control module by means of one or more operations; if the control module receives a confirmation signal within a predetermined period of time, then the control module controls the pump body to start bolus infusion; and if the control module receives a cancellation signal or does not receive the confirmation signal within a predetermined period of time, then the control module controls the pump body to exit the bolus infusion mode. Using the method enables an insulin pump to execute a more reasonable control when carrying out the bolus infusion, i.e., starting, setting and implementation of the bolus infusion, and enables a simple and quick operation.

Absstract of: WO2023081734A1

Certain aspects of the present disclosure relate to methods and systems for predicting glycemic events in a patient induced as a result of physical activity. In certain aspects, a method includes monitoring a plurality of analytes of the patient continuously during a time period to obtain analyte data, the plurality of analytes including at least glucose and lactate. The method further includes processing the analyte data from the time period to determine an intensity level of physical activity engaged by the patient during the time period. The method further includes generating a glycemic event prediction using at least the analyte data for the plurality of analytes and the determination of physical activity intensity. The method further includes generating one or more recommendations for treatment for the patient based, at least in part, on the glycemic event prediction.

Absstract of: WO2023080407A1

An electronic device according to an embodiment can generate logs of a user's blood glucose values obtained through a blood glucose sensor, determine a target event on the basis of the logs and a user's target blood glucose value obtained through the blood glucose sensor, and output a message suggesting a target behavior for the target event. Various other embodiments may be possible.